SHS Gesellschaft für Beteiligungsmanagement mbH
20. July 2020 - Newsletter

SHS invests in Finnish health tech company specialising in epilepsy diagnostics

In the spring, we invested in Finnish medical technology company Neuro Event Labs Oy as part of an international consortium. With its product Nelli™, the health tech specialist from Tampere has developed an AI-powered epilepsy diagnostic tool that can be used by patients at home. Epilepsy is one of the most common neurological disorders, affecting over 65 million individuals worldwide. To provide optimal treatment, it is crucial to be able to clearly define the type and frequency of seizures, which often occur during the night. It has not been possible to achieve this to the desired certainty to date. Consequently, around one third of diagnosed epilepsy patients suffer from uncontrolled seizures despite the availability of possible treatment methods. The Nelli™ system developed by Neuro Event Labs works based on video and audio recordings and is used by patients at home in consultation with their doctor. Nelli™, which is already in use in leading Nordic clinics, provides doctors with extensive information on their patients’ epilepsy status by interpreting their behaviour, movements and sounds. Doctors can respond accordingly and tailor treatment precisely to the individual patient.

This clinical report on an affected patient is worth a read: